Ken Seshimo,
Toshiaki Toshima,
Kenji Mizuno,
Hideaki Ikeda,
Hiroshi Kato,
Masao Yamamura,
Masahito Kodera,
Masahiro Oishi,
Yutaka Yamashita,
Noriaki Tanaka,
Hiraku Fujita,
Koutaro Shibagaki,
Hideaki Taniguchi,
Hiromasa Takeda,
Keita Kobayashi,
Keiko Takita,
Manabu Nishie, Kazuhide Iwakawa
[show abstract]
[hide abstract]
ABSTRACT: We report a case of adenocarcinoma of the small intestine responding to XELOX chemotherapy, leading to a partial metabolic response(PMR). The patient was a 58-year-old male with multiple peritoneal dissemination of adenocarcinoma of the small intestine. Chemotherapy with XELOX(L-OHP 130 mg/m² on day 1 , and capecitabine 1,000 mg/m2 on days 1-14)was performed. After 4 courses, a significant tumor reduction was obtained. This case suggests that chemotherapy with XELOX is a potential regimen for small intestinal adenocarcinoma.
Gan to kagaku ryoho. Cancer & chemotherapy 05/2012; 39(5):833-4.
